Lumos Diagnostics Experiences Surge in US FebriDx Sales, FDA Waiver Decision on Track

Lumos Diagnostics reported a 4.3-fold increase in US sales of its FebriDx respiratory test in Q4 2025, with total revenue of $2.7 million, down 6.9% YoY. The company secured nationwide Medicare reimbursement and is awaiting a CLIA waiver decision by the end of Q1 2026. A pediatric clinical study is underway, and Lumos expanded its European distribution footprint with a new agreement in Lithuania, Estonia, and Latvia. Development services remain a steady contributor, with work on around 12 active projects and a major revenue driver in the Hologic fFN diagnostic program.